EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

EssilorLuxottica Société anonyme (0OMK) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of EssilorLuxottica Société anonyme €89.14, price €143, upside -37.6%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · GB · Home France · ISIN FR0000121667

ES Thin data Sep 29, 2026

EssilorLuxottica Société anonyme

0OMK · LSE

Weakest SetupQuality growthStrongly overvalued and low quality.

!Fair value €89.14 · Strongly overvalued (−37.6%)
!Quality 44/100
!Mixed Growth (revenue 3y +16.3 %/yr)
!Thin margins · 8.1% net margin (TTM)
✓Low debt
·2.8% dividend yield · Safety not assessed
!Narrow moat 34/100
!Evidence only low, so the estimate is less certain
Watch EssilorLuxottica Société anonyme for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€312.88 €124.21 Fair Value €89.14 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.

How to read this chart

60‑month range €124.21 – €312.88 · the €142.95 price screens above the €89.14 fair value. Dashed = 300-day average. As of Sep 29, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EssilorLuxottica designs, manufactures, and distributes ophthalmic lenses, frames, sunglasses, and instruments and equipment in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific.

Show more

EssilorLuxottica designs, manufactures, and distributes ophthalmic lenses, frames, sunglasses, and instruments and equipment in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific. It offers lens, eyewear, contact lenses, reading glasses under Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir Optical, eyexpert, iWear, Humanware, Optifog, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native Eyewear and Bolon, and Foster Grant brands. The company also provides vision assessment, eye pathology diagnosis and treatment, finishing equipment, fitting parameter measurement, small tools, and consumables. In addition, it offers SPECTRALIS, a multimodal imaging platform for diagnosis and treatment; RetinAI; Espansione Group; Cellview Imaging; ANTERION, a multidisciplinary all-in-one anterior segment imaging solution for measurements; apparel, footwear and accessories; and high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. Further, the company designs, develops, markets, and maintains diagnostics, refraction, lens edging and mounting instruments for opticians and prescription laboratories, and measurement; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It sells its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and consumers through the network of brick and mortar retail networks and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica in October 2018. EssilorLuxottica was founded in 1849 and is headquartered in Paris, France.

Stock analysis

EssilorLuxottica Société anonyme (0OMK) currently trades at €142.95, while our model-based Fair Value estimate is €89.14, 37.6% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of €87.23 per share, and 3 of the 23 models we run sit above the €142.95 price.

Bear case: the Dividend Discount group reads lowest at €13.59, and 20 of the 23 models stay below the price. Evidence for this calculation is low.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

EssilorLuxottica Société anonyme reported revenue of €14.4B in FY2020 versus €7.1B in FY2016, a compound +19.3%/yr. Reported net income was €85.0M in FY2020, compounding −43.1%/yr from FY2016.

Key figures

Market cap €76.9B · P/S ratio 2.70 · Dividend yield 2.8% · Net margin 0.6% · Return on equity 6.1% · Return on assets (EBIT) 5.9% · Operating margin 10.2% · Revenue (TTM) €28.5B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 54% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at −38%, 0OMK screens cheaper than that median.

Fair Value models

Bear €89.14 Fair Value €89.14 Bull €89.14
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income €40.31 €37.35 €35.43 73
Growth DCF €115.32 €245.14 €451.78 71
FCF DCF €118.99 €226.59 €500.00 70
All 23 models by family
DCF Models
FCF DCF €118.99 €226.59 €500.00 70
5Y Revenue Exit €34.69 €50.87 €69.30 70
5Y EBITDA Exit €73.91 €138.37 €222.02 70
5Y P/E Exit €30.95 €42.54 €53.61 69
10Y Revenue Exit €60.20 €87.23 €124.00 64
10Y EBITDA Exit €87.37 €154.37 €262.25 63
10Y P/E Exit €57.93 €80.83 €109.80 61
Earnings-Based
Graham-Dodd €1.07 €6.39 €8.90 61
Lynch FV €1.82 €2.59 €3.37 58
PEG = 1.0 €1.82 €2.59 €3.37 55
Dividend Discount
Gordon GGM €7.75 €16.12 €25.57 63
DDM Multi-Stage €7.75 €13.59 €16.92 64
Multiples
P/E Multiple €2.61 €3.48 €4.35 63
P/S Multiple €2.02 €2.69 €3.36 58
P/B Multiple €2.02 €2.69 €3.36 55
EV/EBIT €1.75 €5.32 €8.89 60
EV/EBITDA €57.85 €80.12 €102.40 67
EV/Revenue n/a €1.96 €5.24 50
Asset-Based
NCAV (Graham) €30.00 €40.20 €60.01 54
Growth DCF
Growth DCF €115.32 €245.14 €451.78 71
Rev-Margin DCF €34.69 €52.20 €76.53 69
Economic Profit
Residual Income €40.31 €37.35 €35.43 73
Growth Earnings
Growth-Adj P/E €2.71 €3.87 €5.03 65

Open the full fair value analysis →

Notify me when 0OMK reaches fair value

Put 0OMK on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 49 · Market factors (momentum, volatility) 29

Profitability 18
Margins and returns on capital today
Quality Growth 17
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 58
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 79
Calm price path (market factor)
Momentum 12
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−17.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
17.3% (2016) → 3.1% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
not computed

0OMK screens overvalued: fair value 38% below the price. Compare with Intuitive Surgical, Inc →

Compare EssilorLuxottica Société anonyme with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 190 stocks

Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Bottom 25%
Profitability
Return on equity (TTM) 6.1% · Below median
Return on assets 3.4% · Above median
Net margin (TTM) 8.1% · Above median
Operating margin (TTM) 10.2% · Below median
Growth and dividend
Revenue growth 9.4% · Above median
Dividend yield (TTM) 2.8% · Above median
Balance sheet
Debt / equity 0.29× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 2.77× · Pricier than median
P/S (TTM) 3.13× · Pricier than median
EV/EBITDA 16.9× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $406.63 $348.72 −14%
Becton, Dickinson and Company BDX $178.07 $104.73 −41%
Medline Inc MDLN $34.70 $29.06 −16%
Alcon Inc ALC $63.94 $40.13 −37%
West Pharmaceutical Services, Inc WST $375.65 $137.81 −63%
Sartorius Stedim Biotech S.A DIM €208.20 €54.82 −74%
Straumann Holding STMN CHF 89.80 CHF 45.50 −49%
Sartorius Aktiengesellschaft SRT €206.50 €42.05 −80%
Solventum Corporation SOLV $89.50 $134.36 +50%
Baxter International Inc BAX $23.37 $2.68 −89%

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "EssilorLuxottica Société anonyme Fair Value". https://www.fairvalue-calculator.com/stock/0OMK

Frequently asked questions

Is EssilorLuxottica Société anonyme (0OMK) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of €89.14 versus a price of €142.95, about −38% upside (overvalued).
What is the fair value of 0OMK?
Our model-based fair value for EssilorLuxottica Société anonyme is €89.14 (as of Sep 29, 2026), built from audited fundamentals. The current price: €142.95.
What is the quality score of 0OMK?
EssilorLuxottica Société anonyme has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EssilorLuxottica Société anonyme (0OMK)?
Our model-based price target is the fair value of €89.14 (as of Sep 29, 2026) from 23 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the EssilorLuxottica Société anonyme stock forecast for 2026?
Our models put fair value at €89.14, about −38% upside versus a price of €142.95 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of EssilorLuxottica Société anonyme (0OMK)?
EssilorLuxottica Société anonyme reported trailing-twelve-month revenue of about €28.5B (latest available figure, as of Sep 29, 2026).
Does EssilorLuxottica Société anonyme pay a dividend?
EssilorLuxottica Société anonyme currently shows a dividend yield of about 2.80% relative to its recent price (as of Sep 29, 2026).
What is the intrinsic value of EssilorLuxottica Société anonyme (0OMK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EssilorLuxottica Société anonyme it is €89.14 per share (as of Sep 29, 2026), against a price of €142.95. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is EssilorLuxottica Société anonyme stock overvalued or undervalued in 2026?
As of Sep 29, 2026, 0OMK trades above its calculated fair value: price €142.95, fair value €89.14, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0OMK?
No. The price is what the market pays today (€142.95); the fair value is what the company's own numbers justify (€89.14). For EssilorLuxottica Société anonyme the two are €53.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is EssilorLuxottica Société anonyme worth?
The market values EssilorLuxottica Société anonyme at about €76.9B (market capitalisation, as of Sep 29, 2026). Per share that is €142.95; our models calculate a fair value of €89.14 per share.
How solid is the balance sheet of EssilorLuxottica Société anonyme (0OMK)?
Balance-sheet figures for EssilorLuxottica Société anonyme (as of Sep 29, 2026): return on equity 6.1%, debt of 0.29 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 0OMK from its 52-week high?
EssilorLuxottica Société anonyme trades at €142.95, about 54% below its 52-week high of €312.88 and 3% above the low of €138.43 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €89.14 is for.
Which stocks are comparable to EssilorLuxottica Société anonyme?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, Becton, Dickinson and Company, Medline Inc, Alcon Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EssilorLuxottica Société anonyme stock attractive at the current price?
The data as of Sep 29, 2026: price €142.95, calculated fair value €89.14 (−38%), Quality Score 44/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0OMK calculated?
We run EssilorLuxottica Société anonyme through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €89.14, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. EssilorLuxottica Société anonyme itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EssilorLuxottica Société anonyme (0OMK)?
The closing price on Oct 2, 2026 was €142.95. Our model-based fair value is €89.14, about −38% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EssilorLuxottica Société anonyme right now?
The price sits above even our optimistic bull case (€89.14). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of EssilorLuxottica Société anonyme

How large is the market capitalisation of EssilorLuxottica Société anonyme (0OMK)?
The market capitalisation of EssilorLuxottica Société anonyme is €76.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EssilorLuxottica Société anonyme (0OMK)?
The price-to-sales ratio of EssilorLuxottica Société anonyme is 2.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of EssilorLuxottica Société anonyme (0OMK)?
The dividend yield of EssilorLuxottica Société anonyme is 2.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EssilorLuxottica Société anonyme (0OMK)?
The net margin of EssilorLuxottica Société anonyme is 0.6% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EssilorLuxottica Société anonyme (0OMK)?
The return on equity (ROE) of EssilorLuxottica Société anonyme is 6.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EssilorLuxottica Société anonyme (0OMK)?
On an EBIT basis the return on assets of EssilorLuxottica Société anonyme is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EssilorLuxottica Société anonyme (0OMK)?
The operating margin of EssilorLuxottica Société anonyme is 10.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EssilorLuxottica Société anonyme (0OMK)?
Revenue at EssilorLuxottica Société anonyme is growing +9.4% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EssilorLuxottica Société anonyme (0OMK)?
Earnings per share at EssilorLuxottica Société anonyme are growing −7.7% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch EssilorLuxottica Société anonyme in the live analysis

One click puts EssilorLuxottica Société anonyme on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.